Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track: Imbruvica Snags First-Line CLL Claim; Gilead TAF Strategy Advances

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.


Related Content

Gilead Buys Its Third Priority Review Voucher, But Is The Mania Over?
Priority Review Vouchers Appear To Be Dropping In Price
Keeping Track: Label Expansion For AbbVie/J&J's Imbruvica, Theravance's Vibativ
Imbruvica’s New Label Opens Door For Use With Popular Rituxan Combo
ViiV’s Visibility Grows And Pressure Mounts For What Comes Next
Investor Conference Business Updates, In Brief
FDA's NDA And BLA Approvals
CHMP Positive On Descovy, A Safer HIV Therapy?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts